| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 24 | 2023 | 1577 | 1.790 |
Why?
|
| Tissue Array Analysis | 6 | 2010 | 140 | 0.710 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 97 | 0.630 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2017 | 111 | 0.620 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2021 | 768 | 0.590 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2021 | 268 | 0.540 |
Why?
|
| Prostatectomy | 7 | 2016 | 358 | 0.520 |
Why?
|
| Nephrectomy | 1 | 2017 | 179 | 0.480 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2007 | 1045 | 0.480 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 78 | 0.480 |
Why?
|
| Mesothelioma | 1 | 2017 | 93 | 0.480 |
Why?
|
| Pneumonectomy | 1 | 2017 | 148 | 0.470 |
Why?
|
| Radiotherapy | 1 | 2016 | 145 | 0.470 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 241 | 0.450 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 154 | 0.450 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 450 | 0.390 |
Why?
|
| Biomarkers, Tumor | 7 | 2010 | 1679 | 0.370 |
Why?
|
| Gene Expression Profiling | 4 | 2012 | 1882 | 0.370 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1304 | 0.360 |
Why?
|
| Trans-Activators | 3 | 2008 | 712 | 0.330 |
Why?
|
| Prostate | 4 | 2023 | 437 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2007 | 232 | 0.300 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 116 | 0.290 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 1541 | 0.260 |
Why?
|
| Chromosome Mapping | 2 | 2008 | 1096 | 0.260 |
Why?
|
| Radiosurgery | 2 | 2017 | 147 | 0.240 |
Why?
|
| Translocation, Genetic | 1 | 2007 | 357 | 0.240 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2005 | 39 | 0.230 |
Why?
|
| Exons | 1 | 2007 | 806 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2009 | 1018 | 0.220 |
Why?
|
| Aged | 18 | 2023 | 21456 | 0.220 |
Why?
|
| Prognosis | 9 | 2021 | 5015 | 0.220 |
Why?
|
| Male | 31 | 2023 | 64979 | 0.220 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2004 | 10 | 0.210 |
Why?
|
| Immunohistochemistry | 7 | 2010 | 1714 | 0.210 |
Why?
|
| Middle Aged | 19 | 2023 | 29007 | 0.210 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2004 | 64 | 0.210 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 142 | 0.200 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2023 | 8 | 0.200 |
Why?
|
| Lasers, Solid-State | 1 | 2023 | 21 | 0.200 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2023 | 40 | 0.190 |
Why?
|
| Prostatic Hyperplasia | 1 | 2023 | 122 | 0.190 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2010 | 64 | 0.190 |
Why?
|
| Biopsy, Needle | 5 | 2010 | 234 | 0.180 |
Why?
|
| Humans | 38 | 2023 | 132201 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2012 | 3356 | 0.170 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2021 | 19 | 0.170 |
Why?
|
| DNA Modification Methylases | 1 | 2021 | 50 | 0.170 |
Why?
|
| DNA Repair Enzymes | 1 | 2021 | 43 | 0.170 |
Why?
|
| Laser Therapy | 1 | 2023 | 232 | 0.170 |
Why?
|
| Transcriptional Regulator ERG | 3 | 2008 | 39 | 0.160 |
Why?
|
| Prostate-Specific Antigen | 4 | 2023 | 271 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 623 | 0.140 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2021 | 491 | 0.140 |
Why?
|
| Space Flight | 1 | 2021 | 165 | 0.140 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 2016 | 6 | 0.130 |
Why?
|
| Spinal Neoplasms | 1 | 2017 | 74 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2023 | 7123 | 0.120 |
Why?
|
| DNA-Binding Proteins | 3 | 2008 | 1980 | 0.120 |
Why?
|
| Adult | 12 | 2017 | 31600 | 0.110 |
Why?
|
| Aging | 1 | 2021 | 1251 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2021 | 1122 | 0.110 |
Why?
|
| Burkitt Lymphoma | 2 | 2012 | 141 | 0.110 |
Why?
|
| Prostatic Secretory Proteins | 2 | 2010 | 3 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2017 | 333 | 0.100 |
Why?
|
| Glioblastoma | 1 | 2017 | 373 | 0.100 |
Why?
|
| Reoperation | 1 | 2016 | 853 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2021 | 6569 | 0.100 |
Why?
|
| Guanylate Cyclase | 1 | 2012 | 35 | 0.100 |
Why?
|
| Lymphocytosis | 1 | 2012 | 14 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2009 | 772 | 0.100 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2012 | 42 | 0.100 |
Why?
|
| Neoplasm Staging | 3 | 2017 | 1363 | 0.090 |
Why?
|
| Germ-Line Mutation | 2 | 2012 | 368 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2010 | 2062 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2007 | 2679 | 0.090 |
Why?
|
| Risk Factors | 5 | 2017 | 10944 | 0.090 |
Why?
|
| Genes, BRCA2 | 1 | 2010 | 48 | 0.080 |
Why?
|
| BRCA2 Protein | 1 | 2010 | 51 | 0.080 |
Why?
|
| Genotype | 5 | 2010 | 2702 | 0.080 |
Why?
|
| Oncogenes | 1 | 2010 | 177 | 0.080 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2010 | 100 | 0.080 |
Why?
|
| BRCA1 Protein | 1 | 2010 | 81 | 0.080 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 403 | 0.080 |
Why?
|
| Lung | 1 | 2017 | 1556 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 543 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2009 | 81 | 0.080 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 1 | 2008 | 4 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2008 | 11 | 0.070 |
Why?
|
| Breast Neoplasms | 3 | 2010 | 2681 | 0.070 |
Why?
|
| Treatment Outcome | 4 | 2023 | 13028 | 0.070 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2010 | 153 | 0.070 |
Why?
|
| Racemases and Epimerases | 1 | 2008 | 12 | 0.070 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 63 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2007 | 41 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2007 | 58 | 0.070 |
Why?
|
| Genes, Neoplasm | 1 | 2007 | 87 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 153 | 0.070 |
Why?
|
| Transcription Factors | 2 | 2008 | 2490 | 0.060 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 257 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 3844 | 0.060 |
Why?
|
| Quantitative Trait Loci | 1 | 2008 | 313 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2010 | 766 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 462 | 0.060 |
Why?
|
| Genetic Markers | 1 | 2007 | 618 | 0.060 |
Why?
|
| Alleles | 1 | 2010 | 1684 | 0.060 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2006 | 52 | 0.060 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 68 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 1285 | 0.060 |
Why?
|
| Chromosome Aberrations | 1 | 2007 | 590 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 280 | 0.060 |
Why?
|
| Case-Control Studies | 3 | 2010 | 3414 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2010 | 956 | 0.050 |
Why?
|
| Female | 5 | 2021 | 70754 | 0.050 |
Why?
|
| Genomics | 1 | 2012 | 1652 | 0.050 |
Why?
|
| Receptors, Immunologic | 1 | 2005 | 127 | 0.050 |
Why?
|
| Tobacco, Smokeless | 1 | 2004 | 9 | 0.050 |
Why?
|
| Mutation | 4 | 2010 | 6243 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2008 | 1595 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2017 | 17391 | 0.050 |
Why?
|
| Holmium | 1 | 2023 | 10 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2009 | 2851 | 0.050 |
Why?
|
| Carrier Proteins | 1 | 2008 | 1049 | 0.050 |
Why?
|
| India | 1 | 2004 | 238 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2017 | 99 | 0.050 |
Why?
|
| Radiography | 1 | 2005 | 819 | 0.050 |
Why?
|
| Preoperative Care | 1 | 2005 | 368 | 0.050 |
Why?
|
| Young Adult | 1 | 2017 | 9965 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2012 | 946 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2008 | 1284 | 0.050 |
Why?
|
| Androgen Antagonists | 1 | 2023 | 133 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 796 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2008 | 5173 | 0.050 |
Why?
|
| Disease Progression | 1 | 2008 | 2230 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 569 | 0.040 |
Why?
|
| RNA | 1 | 2005 | 552 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2017 | 14735 | 0.040 |
Why?
|
| Laboratories | 1 | 2021 | 89 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 1554 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2001 | 237 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2001 | 343 | 0.040 |
Why?
|
| Formaldehyde | 2 | 2010 | 39 | 0.040 |
Why?
|
| RNA Interference | 2 | 2012 | 515 | 0.040 |
Why?
|
| Telomere | 1 | 2021 | 222 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 826 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2006 | 1580 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2012 | 454 | 0.040 |
Why?
|
| Biomedical Research | 1 | 2005 | 554 | 0.040 |
Why?
|
| Adolescent | 1 | 2017 | 20557 | 0.040 |
Why?
|
| Smoking | 1 | 2004 | 940 | 0.040 |
Why?
|
| Cancer Pain | 1 | 2017 | 27 | 0.030 |
Why?
|
| Craniotomy | 1 | 2017 | 108 | 0.030 |
Why?
|
| Narcotics | 1 | 2017 | 61 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 3771 | 0.030 |
Why?
|
| Child | 1 | 2017 | 25783 | 0.030 |
Why?
|
| Spine | 1 | 2017 | 147 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2010 | 1574 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 5410 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 1287 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2012 | 4720 | 0.030 |
Why?
|
| Palliative Care | 1 | 2017 | 456 | 0.030 |
Why?
|
| Cyclin D3 | 1 | 2012 | 11 | 0.020 |
Why?
|
| Inhibitor of Differentiation Proteins | 1 | 2012 | 11 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2012 | 32 | 0.020 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 2012 | 33 | 0.020 |
Why?
|
| Genes, myc | 1 | 2012 | 103 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2012 | 302 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2012 | 49 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 430 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 364 | 0.020 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2010 | 26 | 0.020 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2010 | 22 | 0.020 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2010 | 70 | 0.020 |
Why?
|
| Janus Kinases | 1 | 2010 | 32 | 0.020 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2010 | 65 | 0.020 |
Why?
|
| Tissue Fixation | 1 | 2010 | 40 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2010 | 84 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2012 | 343 | 0.020 |
Why?
|
| Cell Line, Tumor | 2 | 2010 | 3691 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2010 | 117 | 0.020 |
Why?
|
| Preventive Medicine | 1 | 2010 | 21 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2012 | 802 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2010 | 130 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2012 | 607 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2012 | 380 | 0.020 |
Why?
|
| Fixatives | 1 | 2009 | 14 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2009 | 41 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 409 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 170 | 0.020 |
Why?
|
| Risk Reduction Behavior | 1 | 2010 | 147 | 0.020 |
Why?
|
| Microdissection | 1 | 2008 | 13 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2009 | 49 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2010 | 764 | 0.020 |
Why?
|
| Kallikreins | 1 | 2008 | 30 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2165 | 0.020 |
Why?
|
| Pedigree | 1 | 2012 | 1723 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2010 | 232 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1 | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 868 | 0.020 |
Why?
|
| Echo-Planar Imaging | 1 | 2008 | 23 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 2900 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 391 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 700 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 423 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2008 | 101 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 293 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 937 | 0.020 |
Why?
|
| Osteopontin | 1 | 2008 | 52 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2010 | 408 | 0.020 |
Why?
|
| Australia | 1 | 2008 | 185 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 322 | 0.020 |
Why?
|
| United Kingdom | 1 | 2008 | 234 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2009 | 228 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1611 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 996 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2007 | 188 | 0.020 |
Why?
|
| Reference Values | 1 | 2008 | 703 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 689 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 2669 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2008 | 1080 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 1128 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 444 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2005 | 3 | 0.010 |
Why?
|
| Contrast Media | 1 | 2009 | 507 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2005 | 9 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2006 | 221 | 0.010 |
Why?
|
| E2F3 Transcription Factor | 1 | 2004 | 11 | 0.010 |
Why?
|
| Cytokines | 1 | 2010 | 1365 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2008 | 906 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 454 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 1461 | 0.010 |
Why?
|
| Gene Expression | 1 | 2008 | 1563 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2004 | 240 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 2138 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2008 | 1250 | 0.010 |
Why?
|
| Genome, Human | 1 | 2009 | 1331 | 0.010 |
Why?
|
| DNA Damage | 1 | 2006 | 511 | 0.010 |
Why?
|
| Genome-Wide Association Study | 1 | 2009 | 1830 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 1099 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 1723 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 3736 | 0.010 |
Why?
|
| Phenotype | 1 | 2006 | 4538 | 0.010 |
Why?
|